CLPT Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

10.05M

+29.33%

-0.200

-0%

12.20M

+43.78%

-0.230

+4.55%

13.40M

+45.42%

-0.210

-0%

Estimates Revision

The market is revising Downward the revenue expectations for ClearPoint Neuro, Inc. (CLPT) for FY2025, with the revenue forecasts being adjusted by -1.08% over the past three months. During the same period, the stock price has changed by -48.48%.

Revenue Estimates for FY2025

Revise Downward

-1.08%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+2.47%

In Past 3 Month

Stock Price

Go Down

-48.48%

In Past 3 Month

2 Analyst Rating

Wall Street analysts forecast CLPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CLPT is 29.00 USD with a low forecast of 28.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

28.00

Averages

29.00

High

30.00

Current: 0.000

Low

28.00

Averages

29.00

High

30.00

B. Riley

Buy

maintain

$20 -> $28

2025-04-25

Reason

B. Riley

Price Target

$20 -> $28

2025-04-25

maintain

Buy

Reason

B. Riley raised the firm's price target on ClearPoint Neuro to $28 from $20 and keeps a Buy rating on the shares following a transfer of coverage. ClearPoint is a medical device company focused on providing image-guided navigation for minimally invasive neuro procedures, the analyst tells investors in a research note. The firm says the company's core business continues to grow over 20% annually, and that it expects significant growth in the future as biopharma partnerships progress towards regulatory approvals and commercial launches.

Stifel

Mathew Blackman

Strong Buy

Maintains

$19 → $25

2025-04-01

Reason

Stifel

Mathew Blackman

Price Target

$19 → $25

2025-04-01

Maintains

Strong Buy

Reason

B. Riley Securities

Neil Chatterji

Strong Buy

Maintains

$15 → $20

2025-01-28

Reason

B. Riley Securities

Neil Chatterji

Price Target

$15 → $20

2025-01-28

Maintains

Strong Buy

Reason

Lake Street

Frank Takkinen

Strong Buy

Maintains

$17 → $30

2025-01-21

Reason

Lake Street

Frank Takkinen

Price Target

$17 → $30

2025-01-21

Maintains

Strong Buy

Reason

Lake Street analyst Frank Takkinen raised the firm's price target on ClearPoint Neuro to $30 from $17 and keeps a Buy rating on the shares. While shares have had a meaningful move, the firm still does not think investors "fully appreciate" the potential of the partner business, says the analyst, who expects a basket of approved combo-therapies to be on the market over time and sees this providing "multiple growth opportunities" for ClearPoint.

Valuation Metrics

The current forward P/E ratio for Clearpoint Neuro Inc (CLPT.O) is -16.90, compared to its 5-year average forward P/E of -17.71. For a more detailed relative valuation and DCF analysis to assess Clearpoint Neuro Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-17.71

Current PE

-16.90

Overvalued PE

-8.51

Undervalued PE

-26.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-23.87

Current EV/EBITDA

-27.66

Overvalued EV/EBITDA

-10.66

Undervalued EV/EBITDA

-37.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

11.27

Current PS

8.36

Overvalued PS

17.34

Undervalued PS

5.20

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

CLPT News & Events

Events Timeline

No data

News

2.0

2025-12-16Benzinga

Cementos Pacasmayo, Rezolve AI, Emerald Holding, and Other Major Stocks Rising on Monday

9.0

2025-12-16NASDAQ.COM

Post-Market Winners: Biotech and Med-Tech Stocks Rise on FDA Developments, Trial Clarity, and Merger Momentum

9.5

2025-11-06SeekingAlpha

ClearPoint Neuro, Inc. Reports GAAP EPS of -$0.21, Falling Short by $0.01; Revenue of $8.86M Misses Expectations by $0.74M

People Also Watch

Frequently Asked Questions

What is Clearpoint Neuro Inc (CLPT) stock price today?

The current price of CLPT is 14.92 USD — it has decreased -2.55 % in the last trading day.

What is Clearpoint Neuro Inc (CLPT)'s business?

ClearPoint Neuro, Inc. is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. It provides both clinical products as well as pre-clinical development services for controlled drug and device delivery. Its flagship product is the ClearPoint Neuro Navigation System. It is engaged with healthcare and research centers in North America, Europe, Asia, and South America. Its primary medical device product, the ClearPoint system, is an integrated system comprised of hardware components, disposable components, and intuitive, menu-driven software. Its ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy for neuro applications under 3.0T magnetic resonance imaging (MRI) guidance. It provides solutions for direct CNS delivery of therapeutics in preclinical studies and clinical trials worldwide. It also offers IRRAflow active fluid-exchange system.

What is the price predicton of CLPT Stock?

What is Clearpoint Neuro Inc (CLPT)'s revenue for the last quarter?

Clearpoint Neuro Inc revenue for the last quarter amounts to 8.86M USD, increased 9.10 % YoY.

What is Clearpoint Neuro Inc (CLPT)'s earnings per share (EPS) for the last quarter?

Clearpoint Neuro Inc. EPS for the last quarter amounts to -0.21 USD, increased 16.67 % YoY.

What changes have occurred in the market's expectations for Clearpoint Neuro Inc (CLPT)'s fundamentals?

How many employees does Clearpoint Neuro Inc (CLPT). have?

Clearpoint Neuro Inc (CLPT) has 115 emplpoyees as of January 10 2026.

What is Clearpoint Neuro Inc (CLPT) market cap?

Today CLPT has the market capitalization of 443.84M USD.